Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Mar 05, 2026
|
Keros Therapeutics Reports Q4 2025 Loss, Full‑Year Profit Driven by Takeda Licensing Deal
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
JANX
Janux Therapeutics, Inc.
Company focuses on tumor-activated oncology therapies (TRACTr/TRACIr), placing JANX squarely in Biotech - Oncology.
|
$863.12M |
$13.96
-2.68%
|
|
CTMX
CytomX Therapeutics, Inc.
CX-2051 is a lead antibody-drug conjugate (ADC) using the PROBODY platform, making Antibody-Drug Conjugates the direct product category.
|
$836.11M |
$4.77
-5.92%
|
|
CSTL
Castle Biosciences, Inc.
Castle Biosciences provides oncology biomarker diagnostics (DecisionDx-Melanoma, DecisionDx-SCC, TissueCypher BE) using gene expression profiling and spatial omics, aligning with Biotech - Oncology.
|
$822.24M |
$27.90
-0.96%
|
|
KALV
KalVista Pharmaceuticals, Inc.
EKTERLY (sebetralstat) is KalVista's lead asset and is an oral small-molecule therapeutic for acute hereditary angioedema, directly reflecting their product category.
|
$817.74M |
$16.21
-0.98%
|
|
GYRE
Gyre Therapeutics, Inc.
Gyre Therapeutics develops and commercializes small-molecule therapeutics (lead Hydronidone/F351 and multiple pipeline agents, plus licensed products) for fibrotic diseases, which fits the 'Oral Small Molecule Therapeutics' category.
|
$797.47M |
$7.80
-5.80%
|
|
PSNL
Personalis, Inc.
Biomarker-driven companion diagnostics align with PSNL's tumor-informed MRD testing framework.
|
$793.02M |
$8.55
-4.20%
|
|
PHAT
Phathom Pharmaceuticals, Inc.
VOQUEZNA (vonoprazan) is an oral small-molecule therapeutic (P-CAB) with GERD and H. pylori indications, representing the company’s core product line.
|
$786.79M |
$10.73
-2.94%
|
|
STKL
SunOpta Inc.
The company functions as a co-manufacturer and private label partner, providing manufacturing services to brands and retailers.
|
$762.50M |
$6.46
+0.08%
|
|
BIOA
BioAge Labs, Inc.
BioAge's lead program BGE-102 is an oral small-molecule therapeutic, and APJ agonists are being developed for obesity, fitting the 'Oral Small Molecule Therapeutics' investable theme.
|
$755.36M |
$20.34
-3.49%
|
|
AHG
Akso Health Group
Cancer therapy/oncology biotech focus and planned oncology centers.
|
$746.25M |
$1.36
+0.47%
|
|
PRME
Prime Medicine, Inc.
Directly develops gene editing therapeutics (Prime Editing) and the core therapeutic platform, i.e., gene therapy.
|
$743.70M |
$3.94
-4.37%
|
|
KURA
Kura Oncology, Inc.
Kura's core business is oncology-focused biotechnology developing ziftomenib and related menin inhibitors for AML, placing it in Biotech - Oncology.
|
$742.12M |
$8.49
-0.70%
|
|
HYEX
Healthy Extracts Inc.
Exclusive rights to an oral delivery technology for nutritional supplements, a distinctive platform that differentiates the company’s product delivery.
|
$718.60M |
$2.35
|
|
ATXS
Astria Therapeutics, Inc.
Astria Therapeutics develops monoclonal antibody therapeutics (navenibart and STAR-0310).
|
$709.95M |
$12.56
-0.16%
|
|
CMPS
COMPASS Pathways plc
Represents the company's focus on developing neuropsychiatric drugs in the CNS space.
|
$676.39M |
$6.78
-3.90%
|
|
PROK
ProKidney Corp.
Core product is rilparencel (REACT), an autologous cell therapy for preserving kidney function in CKD, fitting the Biotech - Cell Therapy category.
|
$656.25M |
$2.23
-0.22%
|
|
DBVT
DBV Technologies S.A.
Viaskin Peanut EPIT patch is a drug-delivery platform; DBV Technologies directly develops and commercializes this patch-based immunotherapy.
|
$624.33M |
$21.97
-3.60%
|
|
SRDX
Surmodics, Inc.
The company provides proprietary drug-delivery platform technologies used on medical devices (SurVeil DCB) and related platforms.
|
$614.58M |
$42.98
|
|
IRWD
Ironwood Pharmaceuticals, Inc.
LINZESS is a peptide-based therapeutic, aligning with the Peptide Therapeutics investable theme.
|
$608.42M |
$3.63
-2.94%
|
|
MGTX
MeiraGTx Holdings plc
Core business involves developing gene therapies using AAV vectors and a riboswitch platform; MeiraGTx is a clinical-stage biotechnology company focused on genetic medicines.
|
$607.38M |
$7.40
-1.99%
|
|
DRUG
Bright Minds Biosciences Inc.
Directly relates to development of neuropsychiatric/CNS therapeutics targeting serotonin receptors.
|
$605.59M |
$78.05
-1.59%
|
|
KE
Kimball Electronics, Inc.
Strategic expansion into Contract Manufacturing Organizations for medical devices aligns with KE's Medical CMO focus.
|
$597.99M |
$24.25
-1.32%
|
|
LXRX
Lexicon Pharmaceuticals, Inc.
Lexicon's pipeline includes oral small-molecule therapeutics pilavapadin (LX9211) and LX9851; these are oral small-molecule drugs, a major product category in their portfolio.
|
$592.34M |
$1.64
+0.31%
|
|
DSGN
Design Therapeutics, Inc.
Company develops small-molecule therapeutics (GeneTAC) targeting inherited nucleotide repeat disorders.
|
$590.55M |
$10.13
-2.31%
|
|
ESPR
Esperion Therapeutics, Inc.
Directly sells/markets cardiovascular drugs (NEXLETOL, NEXLIZET).
|
$586.72M |
$2.77
-4.81%
|
|
IVA
Inventiva S.A.
Inventiva's lanifibranor is an orally administered small-molecule therapeutic for MASH, fitting the 'Oral Small Molecule Therapeutics' tag.
|
$575.89M |
$6.07
+0.75%
|
|
OCGN
Ocugen, Inc.
Ocugen's modifier gene therapy platform and lead retinal candidates (OCU400/OCU410) are gene therapy products targeting vision disorders.
|
$572.92M |
$1.75
-10.46%
|
|
REPL
Replimune Group, Inc.
Replimune is oncology-focused biotech developing oncolytic immunotherapies.
|
$568.71M |
$7.04
-2.90%
|
|
QURE
uniQure N.V.
Core business is development and commercialization of gene therapies (e.g., AMT-130) using viral vectors, i.e., direct gene therapy products.
|
$563.12M |
$10.62
+17.53%
|
|
EMBC
Embecta Corp.
Embecta provides contract manufacturing/partner manufacturing services and potential co-packaging arrangements.
|
$562.31M |
$9.45
-1.66%
|
|
ALLO
Allogene Therapeutics, Inc.
Direct product category: off-the-shelf allogeneic CAR-T cell therapies (Allogene's core platform and pipeline).
|
$561.36M |
$2.31
-8.89%
|
|
KROS
Keros Therapeutics, Inc.
Duchenne muscular dystrophy (DMD) and associated cytopenias are rare diseases, aligning Keros Therapeutics' focused assets to Rare Diseases.
|
$559.27M |
$11.68
-15.18%
|
|
ABSI
Absci Corporation
Absci's core platform is an Antibody Discovery Platform combining AI design with high-throughput wet-lab validation (lab-in-the-loop) for de novo antibody generation.
|
$559.21M |
$3.87
+3.34%
|
|
RIGL
Rigel Pharmaceuticals, Inc.
Rigel's core products are oncology/hematology therapies (TAVALISSE, REZLIDHIA, GAVRETO), fitting Biotech - Oncology.
|
$537.82M |
$29.50
-0.44%
|
|
PRTA
Prothena Corporation plc
Prothena's core assets are monoclonal antibody therapeutics (PRX012, PRX019, PRX123, etc.) across neurodegenerative diseases, including Alzheimer's and other indications.
|
$530.76M |
$9.47
-3.96%
|
|
KMDA
Kamada Ltd.
Biosimilar product distribution is a key existing business line for Kamada's expanded portfolio.
|
$528.47M |
$9.05
-1.52%
|
|
SLS
SELLAS Life Sciences Group, Inc.
SELLAS' immunotherapies (GPS and SLS009) align with Immunology Therapeutics as cancer immunotherapy agents.
|
$526.49M |
$4.09
-18.10%
|
Showing page 10 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
